Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Verapamil Clear all
Completed Phase 2 Interventional Results available

Combination of Hydroxyurea and Verapamil for Refractory Meningiomas

NCT00706810
View directory record Official record
Conditions
Cancer, Brain Cancer, Meningioma
Interventions
Hydroxyurea, Verapamil
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Colchicine and Verapamil ER

NCT00983242
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Verapamil HCl ER
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers

NCT06916897
View directory record Official record
Conditions
Healthy Subjects
Interventions
sevasemten, Verapamil
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

NCT02111317
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP015K
Interventions
ASP015K, verapamil
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers

NCT01471704
View directory record Official record
Conditions
Healthy
Interventions
INX-08189 50 mg, 240 mg verapamil HCL ER, 50 mg dose of INX-08189 and 240 mg verapamil HCL ER
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2012 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke

NCT02235558
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Verapamil
Drug
Lead sponsor
Justin Fraser
Other
Eligibility
21 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 2 Interventional Results available

Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes

NCT02372253
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Verapamil, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 4 Interventional

INVEST: INternational VErapamil SR Trandolapril STudy

NCT00133692
View directory record Official record
Conditions
Hypertension, Coronary Artery Disease
Interventions
Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril
Drug
Lead sponsor
University of Florida
Other
Eligibility
50 Years and older
Enrollment
22,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2011 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 4 Interventional Results available

Ranolazine and Microvascular Angina by PET in the Emergency Department

NCT02052011
View directory record Official record
Conditions
Microvascular Angina
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
30 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Not applicable Interventional Results available

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

NCT00578617
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Rate Control, Ablation Therapy, Rhythm control
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 3 Interventional

Pharmacotherapy of Treatment-Resistant Mania

NCT00518947
View directory record Official record
Conditions
Mania
Interventions
Lithium, verapamil, verapamil plus lithium
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 24, 2011 · Synced Sep 17, 2026, 10:30 PM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Applesauce Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00649805
View directory record Official record
Conditions
Healthy
Interventions
Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 2

NCT00733239
View directory record Official record
Conditions
Opioid Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg

NCT00648050
View directory record Official record
Conditions
Healthy
Interventions
Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Not applicable Interventional Results available

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

NCT00911508
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Left atrial ablation, Rate or Rhythm Control Therapy
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
2,204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
76
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 66 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 17, 2026, 10:30 PM EDT
Withdrawn Phase 4 Interventional

RCVS: The Rational Approach to Diagnosis and Treatment

NCT03150524
View directory record Official record
Conditions
Reversible Cerebral Vasoconstriction Syndrome
Interventions
TCD- cerebral blood flow velocities, Headache pain score, Neurological examination, Repeat Neuroimaging, Nimodipine, Verapamil ER
Diagnostic Test · Behavioral · Other + 1 more
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 17, 2026, 10:30 PM EDT
Terminated Phase 3 Interventional Results available

Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery

NCT01352416
View directory record Official record
Conditions
Heart; Dysfunction Postoperative, Cardiac Surgery
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Sep 17, 2026, 10:30 PM EDT
Withdrawn Phase 4 Interventional

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

NCT06107829
View directory record Official record
Conditions
Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions
Valbenazine Oral Capsule
Drug
Lead sponsor
Stephen Ruedrich
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CiPA Phase 1 ECG Biomarker Validation Study

NCT03070470
View directory record Official record
Conditions
Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions
Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00647673
View directory record Official record
Conditions
Healthy
Interventions
Verapamil HCL Extended-Release Capsules 300 mg, Verelan® PM Extended-Release Capsules 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers

NCT01197781
View directory record Official record
Conditions
Drug Drug Interactions, Healthy Volunteers
Interventions
FOSTAMATIN, Verapamil
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 22, 2010 · Synced Sep 17, 2026, 10:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00648401
View directory record Official record
Conditions
Healthy
Interventions
Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 17, 2026, 10:30 PM EDT
Withdrawn Phase 4 Interventional

Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT)

NCT04234477
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Beta-blocker strategy, Calcium channel blocker strategy, Physician preference strategy
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 17, 2026, 10:30 PM EDT